ResearchIn-Press PreviewOphthalmologyTherapeutics Open Access | 10.1172/jci.insight.178159
1Department of Ophthalmology, Stanford University School of Medicine, Stanford, United States of America
Find articles by Liu, Z. in: JCI | PubMed | Google Scholar
1Department of Ophthalmology, Stanford University School of Medicine, Stanford, United States of America
Find articles by Chen, S. in: JCI | PubMed | Google Scholar
1Department of Ophthalmology, Stanford University School of Medicine, Stanford, United States of America
Find articles by Lo, C. in: JCI | PubMed | Google Scholar
1Department of Ophthalmology, Stanford University School of Medicine, Stanford, United States of America
Find articles by Wang, Q. in: JCI | PubMed | Google Scholar
1Department of Ophthalmology, Stanford University School of Medicine, Stanford, United States of America
Find articles by Sun, Y. in: JCI | PubMed | Google Scholar |
Published November 5, 2024 - More info
Retinitis pigmentosa (RP) is a complex group of inherited retinal diseases characterized by progressive death of photoreceptor cells and eventual blindness. Pde6a, which encodes a cGMP-specific phosphodiesterase, is a crucial pathogenic gene for autosomal recessive RP (RP43); there is no effective therapy for this form of RP. The compact CRISPR/SaCas9 system, which can be packaged into a single adeno-associated virus, holds promise for simplifying effective gene therapy. Here, we demonstrated that all-in-one AAV-SaCas9-mediated Nrl gene inactivation can efficiently prevent retinal degeneration in a RP mouse model with Pde6anmf363/nmf363 mutation. We screened single guide RNAs (sgRNAs) capable of efficiently editing mouse Nrl gene in N2a cells and then achieved effective gene editing by using a single AAV to co-deliver SaCas9 and an optimal Nrl-sg2 into the mouse retina. Excitingly, in vivo inactivation of Nrl improved photoreceptor cell survival and rescued retinal function in treated Pde6a deficient mice. Thus, we showed that a practical, gene-independent method, AAV-SaCas9-mediated Nrl inactivation, holds promise for future therapeutic applications in patients with RP.